| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| MRK | Merck & Company, Inc. | $70.42 | $187.28B | Sell |
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
http://www.zacks.com/stock/news/356445/pharma-stock-roundup-mrk-buys-imdz-fda-grants-priority-review-to-some-candidates?cid=CS-ZC-FT-356445
Feb 22, 2019 - Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
0
Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review
http://www.zacks.com/stock/news/356394/dow-30-stock-roundup-wmt-earnings-beat-mrks-keytruda-sbla-gets-priority-review?cid=CS-ZC-FT-356394
Feb 22, 2019 - The index endured a holiday-shortened but volatile week.
0
Merck Gets Priority Review for Keytruda in Third-Line SCLC
http://www.zacks.com/stock/news/355982/merck-gets-priority-review-for-keytruda-in-third-line-sclc?cid=CS-ZC-FT-355982
Feb 21, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
0
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio
http://www.zacks.com/stock/news/355599/why-merck-mrk-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-355599
Feb 20, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
0
Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study
http://www.zacks.com/stock/news/355533/mercks-keytruda-fails-to-meet-endpoint-in-liver-cancer-study?cid=CS-ZC-FT-355533
Feb 20, 2019 - Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
0
Intercept Reports Positive Top-Line Data for NASH, Shares Up
http://www.zacks.com/stock/news/355517/intercept-reports-positive-top-line-data-for-nash-shares-up?cid=CS-ZC-FT-355517
Feb 20, 2019 - Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
0
Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $10. ...
http://www.gurufocus.com/news/819032/merck--co-inc-mrk-chairman-president--ceo-kenneth-c-frazier-sold-109-million-of-shares
Feb 19, 2019 - Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $10.9 million of Shares, Stocks: MRK, release date:Feb 19, 2019
0
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
https://www.fool.com/investing/2019/02/19/pfizers-forgotten-cancer-pill-is-about-to-become-i.aspx?source=iedfolrf0000001
Feb 19, 2019 - A drug that disappointed in 2018 will get an unexpected dance at the big ball.
0
Merck Gets Priority Review for Keytruda Combo in Kidney Cancer
http://www.zacks.com/stock/news/355193/merck-gets-priority-review-for-keytruda-combo-in-kidney-cancer?cid=CS-ZC-FT-355193
Feb 18, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
0
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat
http://www.zacks.com/stock/news/354853/incyte-incy-q4-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-354853
Feb 14, 2019 - Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
0